Veraxa Biotech's BiTAC — ADC Shows Tumor Regression in Preclinical Breast Cancer Study
Veraxa Biotech presented initial animal proof-of-concept results for its BiTAC-ADC cancer platform on October 13, 2026, at the World ADC Congress. A single 3 mg/kg dose produced strong tumor regression in a breast cancer xenograft model, with efficacy comparable to a conventional ADC. No body weight decline occurred in